NICE
NICE
复制标题
好的
DOI：
--
复制
发表时间：
2018
期刊：
影响因子：
--
通讯作者：
Farhad Dalal
中科院分区：
文献类型：
--
作者：
Farhad Dalal
和中度新型冠状病毒感染病例。结果：数据来源于三个随机临床试验。对严重不良事件(AE)和属于“感染和感染”类别的不良事件总数的荟萃分析结果显示，与标准治疗相比，巴利替尼和托法替尼的安全性更高的证据在统计学上是显著的：对照组严重不良事件的风险比(RR)为0.82[95%，CI 0.69；0.96](P=0.02)，“感染和感染”的风险比为0.78[95%CI 0.63；0.97](P=0.03)。在这两种情况下，RR都赞成使用Januskinase抑制剂。结论：软件分析显示，巴利替尼和托法替尼在新冠肺炎患者中使用时，与发生严重不良反应和感染的风险有关，具有良好的安全性。在更广泛的患者群体中进行各种设计的研究将使人们能够更准确地评估在新冠肺炎大流行期间短期使用Janus激酶抑制剂作为预防性致病疗法的背景下发生继发性细菌感染的风险。
and moderate cases of a new coronavirus infection. Results: Datawere obtained from three randomized clinical trials. A meta-analysis of the results regarding the total number of serious adverse events (AEs) and adverse events belonging to the class "Infections and infestations" showed statistically signi fi cant evidence on the greater safety of baricitinib and tofacitinib in relation to the risks of these events compared with standard therapy: the risk ratio (RR) of serious adverse events in the comparison groups was 0.82 [95%, CI 0.69; 0.96] (p=0.02), the risk ratio of "Infections and in- vasions" was 0.78 [95% CI 0.63;0.97] (p=0.03). In both cases RRwas in favorof the use ofJanuskinaseinhibitors. Conclusions: Theresultsofthemeta-analysisdemonstrated a favorable safety pro fi le of baricitinib and tofacitinib when used in patients with COVID-19 in relation to the risks of developing serious AEs, as well as infections. Conducting studies of various designs in a wider patient population will allow more accurate assessment of the risks of developing secondary bacterial infections against the background of short-term use of Janus kinase inhibitors as part of their use as a preventive pathogenetic therapy during the COVID-19 pandemic.